IDEAYA开始第一阶段试验 新的癌症药物IDE034, 触发5M 支付 生物细胞素。 IDEAYA starts Phase 1 trial of new cancer drug IDE034, triggering $5M payment to Biocytogen.

IDEAYA生物科学已开始第一阶段临床试验,IDE034,这是针对B7H3和PTK7的针对B7H3和PTK7的双重抗体药物结合体,在某些固态肿瘤中共同表现。 IDEAYA Biosciences has begun a Phase 1 clinical trial with IDE034, a bispecific antibody-drug conjugate targeting B7H3 and PTK7, co-expressed in some solid tumors. 试验将评估安全性、可耐性和作为单一疗法的药物动力学,并计划探讨与IDE161的结合。 The trial will assess safety, tolerability, and pharmacokinetics as a monotherapy, with plans to explore combinations with IDE161. 该里程碑触发了向生物细胞原体支付500万美元的款项,生物细胞原体利用基因编辑平台开发了IDE034。 The milestone triggers a $5 million payment to Biocytogen, which developed IDE034 using gene-editing platforms. 以北京为基地,开展全球行动,在抗体发现方面进行280多次协作和专门研究。 Biocytogen, based in Beijing with global operations, has over 280 collaborations and specializes in antibody discovery.